Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ChronoScale Holdings CorpEKSO · Entity 4331 | Director | November 10, 2020 | November 12, 2020 |
| MariaDB plcMRDB · Entity 86860 | Director | June 29, 2023 | June 30, 2023 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | January 02, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ChronoScale Holdings Corp
Report date November 10, 2020 · Filed November 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Puissance Cross-Border Opportunities II LLC | 29,828 |
Reported balance
After 2020-11-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-11-10 · Other · Disposed 744,572 · Balance 29,828 F1: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F2: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 9,958 |
Reported balance
Holding disclosure · report date 2020-11-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,958 |
Filing footnotes · ownership attribution and instrument terms
F1: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests.
F2: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
MariaDB plc
Report date June 29, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,659,568 |
Reported balance
After 2023-06-29 transaction · row 1
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 182,291 · Balance 2,659,568 F1: Represents a restricted stock unit award that will fully vest upon the earlier of (i) the one-year anniversary of the grant date and (ii) the day immediately prior to the Company's annual meeting of shareholders that next occurs after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award that will fully vest upon the earlier of (i) the one-year anniversary of the grant date and (ii) the day immediately prior to the Company's annual meeting of shareholders that next occurs after the grant date.
ViewRay, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,117 |
Ending reported balance
After 2019-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-01-02 · Grant · Acquired 7,305 · Balance 15,449 F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date. F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $45,000. Row 2 · 2019-01-02 · Grant · Acquired 18,668 · Balance 34,117 F3: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $45,000.
F3: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Angel Pond Holdings Corp
Report date December 16, 2022 · Filed December 19, 2022
Jointly reported with Xie Shihuang, Lionyet International Ltd.
Section 16 reporting ended · disclosed 2022-12-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee Explanation of Responses | 0 |
Reported balance
After 2022-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-16 · Other · Disposed 6,637,870 · Balance 0 F1: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F2: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA. F3: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercised voting and investment power with respect to the Class B ordinary shares, par value $0.0001 per share, held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may have been deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares").
F2: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA.
F3: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercised voting and investment power with respect to the Class B ordinary shares, par value $0.0001 per share, held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may have been deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang.
Bellerophon Therapeutics, Inc.
Report date October 13, 2023 · Filed October 16, 2023
Jointly reported with Puissance Capital Management LP, Puissance Life Science Opportunities Fund VI, Puissance Capital Fund (GP) LLC
Section 16 reporting ended · disclosed 2023-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-13 · Sale · Disposed 1,076,841 · Balance 0 |
Tracon Pharmaceuticals, Inc.
Report date December 05, 2019 · Filed December 11, 2019
Jointly reported with Puissance Cross-Border Opportunities V LLC, Puissance Cross-Border Opportunities IV LLC, Puissance Capital Management LP, Puissance Capital Fund (GP) LLC, Puissance Capital Management (GP) LLC
Section 16 reporting ended · disclosed 2019-12-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 416,182 |
Reported balance
After 2019-12-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-12-05 · Sale · Disposed 43,996 · Balance 416,182 F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock. F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 76,048 |
Reported balance
After 2019-12-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-12-09 · Sale · Disposed 340,134 · Balance 76,048 F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock. F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2024-03-27 | IndirectBy funds | 460,178 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 460,178 F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock.
F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC.
F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock.
F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC.
F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 13, 2023 Filed Oct 16, 2023 20:51 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 1,076,841 | $0.10 | $111,776.10 |
DisclosureSEC source: 0001760460-23-000008 · primary_doc.xml · nonDerivative · entry 1 Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 18:16 UTC | MariaDB plc MRDB · Entity 86860 | GrantOrdinary Shares | 182,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-007045 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,659,568 F1 · shares: Represents a restricted stock unit award that will fully vest upon the earlier of (i) the one-year anniversary of the grant date and (ii) the day immediately prior to the Company's annual meeting of shareholders that next occurs after the grant date. Read SEC document |
| June 07, 2023 Filed Jun 7, 2023 21:21 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 134,421 | $0.83 | $111,569.43 |
DisclosureSEC source: 0001760460-23-000006 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,076,841 Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:10 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (Right to Buy) · Derivative | 14,607 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001104659-23-069905 · tm2318251-3_4seq1.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,607 Underlying: Common Stock · 14,607 shares Expires 2033-06-07 F1 · date: This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023. F2 · derivative.exercise_date: This option vests in full on June 7, 2024. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:55 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | SaleCommon Stock | 560,000 | $9.46 | $5,297,600.00 |
DisclosureSEC source: 0001760460-23-000003 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,211,262 Read SEC document |
| May 11, 2023 Filed May 15, 2023 20:30 UTC | MariaDB plc MRDB · Entity 86860 | GrantOrdinary Shares | 48,342 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005921 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,477,277 F1 · shares: Represents a restricted stock unit award that vests in full on the day prior to the Company's 2023 annual meeting of shareholders. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 16:45 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (right to buy) · Derivative | 29,000 | $1.52 Strike: $1.52 | $44,080.00 |
DisclosureSEC source: 0001415889-23-002456 · form4-02142023_040222.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2033-02-10 Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 18:13 UTC | Angel Pond Holdings Corp POND · Entity 121474 | OtherClass B Ordinary Shares · Derivative | 6,637,870 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-039040 · doc4.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · Chief Executive Officer · 10% owner Xie Shihuang · CIK 0001848676 · 10% owner Lionyet International Ltd. · CIK 0001848059 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 6,637,870 shares Expires not disclosed F1 · derivative.exercise_price: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F1 · kind: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F1 · shares: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F2 · price: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA. F2 · derivative.exercise_date: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA. F2 · derivative.expiration_date: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA. F1 · derivative.underlying_shares: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F3 · ownership.nature: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercised voting and investment power with respect to the Class B ordinary shares, par value $0.0001 per share, held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may have been deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. Read SEC document |
| December 16, 2022 Filed Dec 19, 2022 17:41 UTC | MariaDB plc MRDB · Entity 86860 | GrantOrdinary Shares | 2,428,935 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-039032 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,428,935 F1 · kind: On December 16, 2022, MariaDB plc, an Irish public limited company (formerly named Mangomill plc, the "Issuer") announced the completion of the business combination between Angel Pond Holdings Corporation, a Cayman Islands exempted company ("APHC") and MariaDB Corporation Ab, a Finnish private limited liability company ("MariaDB") with and into the Issuer, with Issuer continuing as the surviving corporation (the "Business Combination"), pursuant to a business combination agreement, dated as of January 31, 2022, by and among the Issuer, APHC, MariaDB, and Meridian MergerSub Inc., a Cayman Islands exempted company and wholly owned subsidiary of the Issuer (the "Merger Agreement"). F2 · kind: In connection with the Business Combination, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting person was cancelled and converted into the right to receive one ordinary share, nominal value $0.01 per share, of the Issuer, subject to the terms and conditions of the Merger Agreement. F1 · price: On December 16, 2022, MariaDB plc, an Irish public limited company (formerly named Mangomill plc, the "Issuer") announced the completion of the business combination between Angel Pond Holdings Corporation, a Cayman Islands exempted company ("APHC") and MariaDB Corporation Ab, a Finnish private limited liability company ("MariaDB") with and into the Issuer, with Issuer continuing as the surviving corporation (the "Business Combination"), pursuant to a business combination agreement, dated as of January 31, 2022, by and among the Issuer, APHC, MariaDB, and Meridian MergerSub Inc., a Cayman Islands exempted company and wholly owned subsidiary of the Issuer (the "Merger Agreement"). F2 · price: In connection with the Business Combination, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting person was cancelled and converted into the right to receive one ordinary share, nominal value $0.01 per share, of the Issuer, subject to the terms and conditions of the Merger Agreement. Read SEC document |
| January 28, 2022 Filed Feb 2, 2022 09:10 UTC | Angel Pond Holdings Corp POND · Entity 121474 | OtherClass B Ordinary Shares · Derivative | 0 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-004048 · doc4.xml · derivative · entry 1 Xie Shihuang · CIK 0001848676 · 10% owner Lionyet International Ltd. · CIK 0001848059 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 6,637,870 Underlying: Class A Ordinary Shares · 0 shares Expires not disclosed F1 · derivative.exercise_price: On January 28, 2022, Angel Pond Partners LLC, Lionyet International Ltd., Theodore Wang and Shihuang Xie agreed to sell 10,000 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") pursuant to a forward purchase agreement. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Principal Shareholders," the obligation to deliver the Class B Shares pursuant to the prepaid forwards is triggered by the consummation of an initial business combination. Until the transfers are consummated, Angel Pond Partners LLC will retain total voting and disposition control over the founder shares subject to the forward purchase agreements, subject to the future delivery obligations. F2 · derivative.exercise_price: (Continued from Footnote 1) As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · kind: On January 28, 2022, Angel Pond Partners LLC, Lionyet International Ltd., Theodore Wang and Shihuang Xie agreed to sell 10,000 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") pursuant to a forward purchase agreement. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Principal Shareholders," the obligation to deliver the Class B Shares pursuant to the prepaid forwards is triggered by the consummation of an initial business combination. Until the transfers are consummated, Angel Pond Partners LLC will retain total voting and disposition control over the founder shares subject to the forward purchase agreements, subject to the future delivery obligations. F2 · kind: (Continued from Footnote 1) As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · price: On January 28, 2022, Angel Pond Partners LLC, Lionyet International Ltd., Theodore Wang and Shihuang Xie agreed to sell 10,000 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") pursuant to a forward purchase agreement. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Principal Shareholders," the obligation to deliver the Class B Shares pursuant to the prepaid forwards is triggered by the consummation of an initial business combination. Until the transfers are consummated, Angel Pond Partners LLC will retain total voting and disposition control over the founder shares subject to the forward purchase agreements, subject to the future delivery obligations. F2 · price: (Continued from Footnote 1) As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.exercise_date: On January 28, 2022, Angel Pond Partners LLC, Lionyet International Ltd., Theodore Wang and Shihuang Xie agreed to sell 10,000 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") pursuant to a forward purchase agreement. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Principal Shareholders," the obligation to deliver the Class B Shares pursuant to the prepaid forwards is triggered by the consummation of an initial business combination. Until the transfers are consummated, Angel Pond Partners LLC will retain total voting and disposition control over the founder shares subject to the forward purchase agreements, subject to the future delivery obligations. F2 · derivative.exercise_date: (Continued from Footnote 1) As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.expiration_date: On January 28, 2022, Angel Pond Partners LLC, Lionyet International Ltd., Theodore Wang and Shihuang Xie agreed to sell 10,000 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") pursuant to a forward purchase agreement. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Principal Shareholders," the obligation to deliver the Class B Shares pursuant to the prepaid forwards is triggered by the consummation of an initial business combination. Until the transfers are consummated, Angel Pond Partners LLC will retain total voting and disposition control over the founder shares subject to the forward purchase agreements, subject to the future delivery obligations. F2 · derivative.expiration_date: (Continued from Footnote 1) As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F3 · ownership.nature: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercise voting and investment power with respect to the Class B ordinary shares held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may also be deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 16:10 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Options (right to buy) · Derivative | 21,828 | $3.10 Strike: $3.10 | $67,666.80 |
DisclosureSEC source: 0001415889-22-000190 · form4-01042022_040130.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,634 Underlying: Common Stock · 21,828 shares Expires 2031-12-31 Read SEC document |
| July 02, 2021 Filed Jul 7, 2021 17:18 UTC | Angel Pond Holdings Corp POND · Entity 121474 | OtherClass B Ordinary Shares · Derivative | 549,630 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-045864 · doc4.xml · derivative · entry 1 Xie Shihuang · CIK 0001848676 · 10% owner Lionyet International Ltd. · CIK 0001848059 · 10% owner Wang Theodore T · CIK 0001694061 · Director · Chief Executive Officer · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 6,637,870 Underlying: Class A Ordinary Shares · 549,630 shares Expires not disclosed F1 · derivative.exercise_price: On July 2, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 549,630 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with the partial exercise of the underwriters' over-allotment option. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · kind: On July 2, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 549,630 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with the partial exercise of the underwriters' over-allotment option. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · price: On July 2, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 549,630 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with the partial exercise of the underwriters' over-allotment option. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.exercise_date: On July 2, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 549,630 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with the partial exercise of the underwriters' over-allotment option. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.expiration_date: On July 2, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 549,630 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with the partial exercise of the underwriters' over-allotment option. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F2 · ownership.nature: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercise voting and investment power with respect to the Class B ordinary shares held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may also be deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. Read SEC document |
| June 07, 2021 Filed Jun 8, 2021 12:37 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 8,189 | $4.00 | $32,756.00 |
DisclosureSEC source: 0001760460-21-000004 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,771,262 F1 · ownership.direct: 1. These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| May 18, 2021 Filed May 20, 2021 13:22 UTC | Angel Pond Holdings Corp POND · Entity 121474 | OtherClass B Ordinary Shares · Derivative | 1,437,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-034336 · doc4.xml · derivative · entry 1 Xie Shihuang · CIK 0001848676 · 10% owner Lionyet International Ltd. · CIK 0001848059 · 10% owner Wang Theodore T · CIK 0001694061 · Director · Chief Executive Officer · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Explanation of Responses Disclosed balance after: 7,187,500 Underlying: Class A Ordinary Shares · 1,437,500 shares Expires not disclosed F1 · derivative.exercise_price: On May 18, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 1,437,500 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with a reduction of the number of shares issued in the Issuer's initial public offering. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · kind: On May 18, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 1,437,500 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with a reduction of the number of shares issued in the Issuer's initial public offering. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · price: On May 18, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 1,437,500 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with a reduction of the number of shares issued in the Issuer's initial public offering. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.exercise_date: On May 18, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 1,437,500 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with a reduction of the number of shares issued in the Issuer's initial public offering. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F1 · derivative.expiration_date: On May 18, 2021, Angel Pond Partners LLC (the "Sponsor") forfeited for no consideration 1,437,500 Class B Ordinary Shares, par value $0.0001 per share (the "Class B Shares"), of Angel Pond Holdings Corp. (the "Issuer") in connection with a reduction of the number of shares issued in the Issuer's initial public offering. As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. F2 · ownership.nature: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercise voting and investment power with respect to the Class B ordinary shares held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may also be deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 304,286 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 3 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 685,236 Underlying: Common Stock · 304,286 shares Expires 2022-09-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantWarrants (Right to buy) · Derivative | 380,950 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · derivative · entry 2 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,950 Underlying: Common Stock · 380,950 shares Expires 2023-11-29 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 26, 2021 Filed Apr 26, 2021 12:39 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 609,231 | $4.00 | $2,436,924.00 |
DisclosureSEC source: 0001760460-21-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,763,077 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| November 10, 2020 Filed Nov 12, 2020 16:07 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | OtherCommon Stock | 744,572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-057907 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Puissance Cross-Border Opportunities II LLC Disclosed balance after: 29,828 F1 · kind: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F1 · price: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F2 · ownership.direct: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 16:04 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 6,509 | $10.12 Strike: $10.12 | $65,871.08 |
DisclosureSEC source: 0001600132-20-000104 · wf-form4_160011382783695.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,806 Underlying: Common Stock · 6,509 shares Expires 2030-09-10 Read SEC document |
| July 23, 2020 Filed Jul 27, 2020 16:42 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 7,383 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043737 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,958 F1 · price: The grant consists of RSUs that fully vest one year from the date of grant, or July 23, 2021. F2 · balance_after: After taking into account the 1-for-15 reverse stock split effective March 24, 2020. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 16:01 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 2,600 | $12.87 | $33,454.20 |
DisclosureSEC source: 0001600132-20-000062 · wf-form4_159173289350800.xml · nonDerivative · entry 2 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,913 Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 16:01 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 4,986 | $12.72 | $63,441.86 |
DisclosureSEC source: 0001600132-20-000062 · wf-form4_159173289350800.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,313 Read SEC document |
| May 21, 2020 Filed May 22, 2020 07:25 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 1,153,846 | $13.00 | $14,999,998.00 |
DisclosureSEC source: 0001760460-20-000002 · primary_doc.xml · nonDerivative · entry 1 Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,153,846 F1 · ownership.direct: These securities are held directly by Puissance Life Science Opportunities Fund VI and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Life Science Opportunities Fund VI; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Life Science Opportunities Fund VI; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Persons each disclaim beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that any Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 10:47 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | OtherCommon Stock | 553,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001718111-20-000001 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities III LLC · CIK 0001718111 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Puissance Cross-Border Opportunities III LLC Disclosed balance after: 0 F1 · kind: Puissance Cross-Border Opportunities III LLC made an in-kind distribution of an aggregate 553,250 shares of the Issuer's common stock to its limited partners in connection with the redemption of partnership interests. F1 · price: Puissance Cross-Border Opportunities III LLC made an in-kind distribution of an aggregate 553,250 shares of the Issuer's common stock to its limited partners in connection with the redemption of partnership interests. F2 · ownership.direct: These securities are held directly by Puissance Cross-Border Opportunities III LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities III LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities III LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 20:42 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | OtherCommon Stock | 8,918,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001717781-20-000001 · primary_doc.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Puissance Cross-Border Opportunities II LLC Disclosed balance after: 11,616,000 F1 · kind: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 8,918,898 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F1 · price: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 8,918,898 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F2 · ownership.direct: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:58 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantStock Option (right to buy) · Derivative | 136,496 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-004378 · doc4.xml · derivative · entry 3 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,496 Underlying: Common Stock · 136,496 shares Expires 2030-01-16 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of July 1, 2019. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 20:58 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 19,445 | $0.45 | $8,750.25 |
DisclosureSEC source: 0001209191-20-004378 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,624 Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 10:47 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 340,134 | $2.92 | $993,191.28 |
DisclosureSEC source: 0001733439-19-000001 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 76,048 F3 · shares: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock. F4 · ownership.direct: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC. Read SEC document |
| December 05, 2019 Filed Dec 11, 2019 10:47 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 43,996 | $3.05 | $134,187.80 |
DisclosureSEC source: 0001733439-19-000001 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Wang Theodore T · CIK 0001694061 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 416,182 F1 · shares: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock. F2 · ownership.direct: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC. Read SEC document |
| November 25, 2019 Filed Nov 25, 2019 16:52 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 7,193 | $0.39 | $2,773.62 |
DisclosureSEC source: 0001600132-19-000164 · wf-form4_157471874347219.xml · nonDerivative · entry 3 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,922 Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 16:52 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 1,050 | $0.37 | $393.54 |
DisclosureSEC source: 0001600132-19-000164 · wf-form4_157471874347219.xml · nonDerivative · entry 2 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,729 Read SEC document |
| November 21, 2019 Filed Nov 25, 2019 16:52 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 200 | $0.37 | $74.00 |
DisclosureSEC source: 0001600132-19-000164 · wf-form4_157471874347219.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,679 Read SEC document |
| September 26, 2019 Filed Sep 30, 2019 16:54 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 46,266 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001600132-19-000136 · wf-form4_156987686289140.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,482 Underlying: Common Stock · 46,266 shares Expires 2029-09-26 Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 11:46 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 50,000 | $0.64 | $31,905.00 |
DisclosureSEC source: 0001600132-19-000097 · wf-form4_156052720172568.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,479 Read SEC document |
| May 22, 2019 Filed May 24, 2019 09:30 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 27,500 | $0.60 | $16,533.00 |
DisclosureSEC source: 0001600132-19-000091 · wf-form4_155870463818500.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,479 Read SEC document |
| May 21, 2019 Filed May 22, 2019 11:15 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 43,280 | $0.61 | $26,370.50 |
DisclosureSEC source: 0001600132-19-000086 · wf-form4_155853809255361.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,979 Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 16:22 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | PurchaseCommon Stock | 450,000 | $0.70 | $315,000.00 |
DisclosureSEC source: 0001600132-19-000044 · wf-form4_154845132884181.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,699 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 20:20 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 18,668 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-19-000200 · ownership.xml · nonDerivative · entry 2 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,117 F3 · shares: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 20:20 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 7,305 | $6.16 | $44,998.80 |
DisclosureSEC source: 0000950103-19-000200 · ownership.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,449 F1 · shares: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $45,000. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 21:50 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 19,116 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0000950103-18-015068 · dp100069_4-wang.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,116 Underlying: Common Stock · 19,116 shares Expires 2028-12-21 F1 · derivative.exercise_date: All of the shares subject to the option had vested and were exercisable as of December 2018. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 10:14 UTC Amendment | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000016 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | SaleCommon Stock | 4,326 | $1.21 | $5,234.46 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 2 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,601,768 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 09:39 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | PurchaseCommon Stock | 4,326 | $1.13 | $4,888.38 |
DisclosureSEC source: 0001733439-18-000015 · primary_doc.xml · nonDerivative · entry 1 Puissance Cross-Border Opportunities V LLC · CIK 0001733439 · 10% owner Puissance Cross-Border Opportunities IV LLC · CIK 0001718140 · 10% owner Puissance Life Science Opportunities Fund VI · CIK 0001760460 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Wang Theodore T · CIK 0001694061 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By funds Disclosed balance after: 4,606,094 F4 · ownership.direct: The purchase and sale of 4,326 shares of Common Stock were under the fund Puissance Life Science Opportunities Fund VI. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 21:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantEmployee Stock Option (right to buy) · Derivative | 41,000 | $0.00 Strike: $1.79 | $0.00 |
DisclosureSEC source: 0001209191-18-045772 · doc4.xml · derivative · entry 3 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common Stock · 41,000 shares Expires 2028-08-03 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on the one-month anniversary of June 7, 2018. Read SEC document |
| August 03, 2018 Filed Aug 7, 2018 21:05 UTC | ChronoScale Holdings Corp EKSO · Entity 4331 | GrantCommon Stock | 19,179 | $1.79 | $34,330.41 |
DisclosureSEC source: 0001209191-18-045772 · doc4.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner Puissance Cross-Border Opportunities II LLC · CIK 0001717781 · 10% owner Puissance Capital Fund (GP) LLC · CIK 0001695347 · 10% owner Puissance Capital Management LP · CIK 0001658437 · 10% owner Puissance Capital Management (GP) LLC · CIK 0001695339 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,179 Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 17:02 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 1,928 | $8.18 | $15,771.04 |
DisclosureSEC source: 0000950103-18-009419 · dp94310_4-wang.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,144 F1 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $15,778. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 17:40 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 2,808 | $7.12 | $19,992.96 |
DisclosureSEC source: 0000950103-18-008366 · dp93196_4-wang.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,216 F1 · shares: 1/6th of these shares shall vest and become exercisable on the last day of each calendar month beginning on July 31, 2018, such that 100% of the shares will be vested on December 31, 2018, subject to the Reporting Person remaining a service provider through each such vesting date. F2 · price: These shares were issued to the reporting person pursuant to ViewRay, Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $20,000. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 16:32 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantCommon Stock | 13,699 | $0.00 | $0.00 |
DisclosureSEC source: 0001600132-18-000098 · wf-form4_152995871323145.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,699 Read SEC document |
| June 13, 2018 Filed Jun 13, 2018 20:05 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001209191-18-037613 · doc4.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.